Protocolo de Actuación en Mieloma múltiple - Sociedad Asturiana ...

31. Pönisch et al. Combined bendamustine, prednisolone and thalidomide for refractory or
relapsed multiple myeloma after autologous stem-cell transplantation or conventional
chemotherapy: results of a Phase I clinical trial.Br J Haematol 2008; 143: 191-200
32. Rajkumar SV et al. Blood 2011: 17: 4691-4995
33. Reece D et al. Influence of cytogenetics in patients with relapsed or refractory multiple
myeloma treated with lenalidomide plus dexametasone: adeverse effect of deletion 17p13.
Blood 2009; 114: 522-25
34. Richardson PG, Sonneveld P, Schuster MW et al. Assessment of Proteasome Inhibition for
Extending Remissions (APEX) Investigators. Bortezomib or high-dose dexamethasone for
relapsed multiple myeloma. N Engl J Med. 2005; 352(24):2487-98
35. Richardson PG, Jagannath S, Jakubowiak, A.Phase II Trial of Lenalidomide, Bortezomib, and
Dexamethasone In Patients (pts) with Relapsed and Relapsed/Refractory Multiple Myeloma
(MM): Updated Efficacy and Safety Data After >2 Years of Follow-up. Blood 2010;abst
.3049
36. Richardson Pg, Alsina M, Weber D et al. Phase II Study of the Pan-Deacetylase Inhibitor
Panobinostat in Combination with Bortezomib and Dexamethasone in Relapsed and
Bortezomib-Refractory Multiple Myeloma (PANORAMA 2)
Blood 2011; 118: abst.814.
37. San Miguel JM, Dimopoulus MA, Staadtmauer E et al. Effects of lenalidomide and
dexametasone treatment duration on survival in patients with relapsed or refractory multiple
myeloma treated with lenalidomide amd dexametasone. Clin Lymphoma Myeloma Leuk
2011; 11: 38-43
38. Schilling G, Hansen T, Shimoni A et al et al. Impact of genetic abnormalities on survival after
allogeneic hematopoietic stem cell transplantation in multiple myeloma. Leukemia 2010; 22:
1250-5
39. Stadtmauer E, Weber D, Niesvizky R et al. Lenalidomide in combination with dexametasone
at first relapse in comparison with its use as late salvage therapy in relapsed or refractory
multiple myeloma. Eur J Haematol 2009; 82: 426-432
40. Van de Donk N, Lokhorst H, Dimopoulus MA et al. Treatment relapsed and refractory
multiple myeloma in the era of novel agents. Cancer Treatment Reviews 2011; 37: 265-88
41. Vij, Jonathan L. Kaufman et al , Final Results From the Bortezomib-naïve Group of PX-171-
004, a Phase 2 Study of Single-Agent Carfilzomib in Patients with Relapsed and/or Refractory
MM. Blood 2011:118: abst. 813
42. Weber DM, Chen C, Niesvizky R et al. Multiple Myeloma (009) Study Investigators.
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J
Med. 2007; 357(21):2133-42
Grupo Asturiano de Linfoma y Mieloma
71